{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:22:27Z","timestamp":1707524547325},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,13]]},"DOI":"10.7759\/cureus.24126","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T01:22:30Z","timestamp":1649899350000},"source":"Crossref","is-referenced-by-count":2,"title":["Bullous Pemphigoid Following the Moderna mRNA-1273 Vaccine"],"prefix":"10.7759","author":[{"given":"Amar D","family":"Desai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radhika","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attiya","family":"Haroon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy","family":"Wassef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30120-1","article-title":"An interactive web-based dashboard to track COVID-19 in real time","volume":"20","author":"Dong E","year":"2020","unstructured":"Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020, 20:533-4. 10.1016\/S1473-3099(20)30120-1","journal-title":"Lancet Infect Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-021-00847-2","article-title":"COVID-19 vaccines and decreased transmission of SARS-CoV-2","volume":"29","author":"Vitiello A","year":"2021","unstructured":"Vitiello A, Ferrara F, Troiano V, La Porta R. COVID-19 vaccines and decreased transmission of SARS-CoV-2. Inflammopharmacology. 2021, 29:1357-60. 10.1007\/s10787-021-00847-2","journal-title":"Inflammopharmacology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n970","article-title":"Covid-19: US suspends Johnson and Johnson vaccine rollout over blood clots","volume":"373","author":"Mahase E","year":"2021","unstructured":"Mahase E. Covid-19: US suspends Johnson and Johnson vaccine rollout over blood clots. BMJ. 2021, 373:n970. 10.1136\/bmj.n970","journal-title":"BMJ"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/08830185.2021.1939696","article-title":"Adverse rare events to vaccines for COVID-19: from hypersensitivity reactions to thrombosis and thrombocytopenia","author":"Novak N","year":"2021","unstructured":"Novak N, Tordesillas L, Cabanillas B. Adverse rare events to vaccines for COVID-19: from hypersensitivity reactions to thrombosis and thrombocytopenia. Int Rev Immunol. 2021, 1-10. 10.1080\/08830185.2021.1939696","journal-title":"Int Rev Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.03.092","article-title":"Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases","volume":"85","author":"McMahon DE","year":"2021","unstructured":"McMahon DE, Amerson E, Rosenbach M, et al.. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol. 2021, 85:46-55. 10.1016\/j.jaad.2021.03.092","journal-title":"J Am Acad Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2021.05.010","article-title":"A case of severe cutaneous adverse reaction following administration of the Janssen Ad26.COV2.S COVID-19 vaccine","volume":"13","author":"Lospinoso K","year":"2021","unstructured":"Lospinoso K, Nichols CS, Malachowski SJ, Mochel MC, Nutan F. A case of severe cutaneous adverse reaction following administration of the Janssen Ad26.COV2.S COVID-19 vaccine. JAAD Case Rep. 2021, 13:134-7. 10.1016\/j.jdcr.2021.05.010","journal-title":"JAAD Case Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2020.3019","article-title":"Should we mandate a COVID-19 vaccine for children?","volume":"175","author":"Opel DJ","year":"2021","unstructured":"Opel DJ, Diekema DS, Ross LF. Should we mandate a COVID-19 vaccine for children?. JAMA Pediatr. 2021, 175:125-6. 10.1001\/jamapediatrics.2020.3019","journal-title":"JAMA Pediatr"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29340","article-title":"COVID-19 vaccination for children with cancer","volume":"69","author":"Kotecha RS","year":"2022","unstructured":"Kotecha RS. COVID-19 vaccination for children with cancer. Pediatr Blood Cancer. 2022, 69:e29340. 10.1002\/pbc.29340","journal-title":"Pediatr Blood Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-017-0813-0","article-title":"Three case reports of post immunization and post viral bullous pemphigoid: looking for the right trigger","volume":"17","author":"Baroero L","year":"2017","unstructured":"Baroero L, Coppo P, Bertolino L, Maccario S, Savino F. Three case reports of post immunization and post viral bullous pemphigoid: looking for the right trigger. BMC Pediatr. 2017, 17:60. 10.1186\/s12887-017-0813-0","journal-title":"BMC Pediatr"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s12519-021-00465-6","article-title":"Expert consensus on COVID-19 vaccination in children","volume":"17","author":"Zheng YJ","year":"2021","unstructured":"Zheng YJ, Wang XC, Feng LZ, et al.. Expert consensus on COVID-19 vaccination in children. World J Pediatr. 2021, 17:449-57. 10.1007\/s12519-021-00465-6","journal-title":"World J Pediatr"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2002.tb00223.x","article-title":"Childhood bullous pemphigoid following hepatitis B immunization","volume":"29","author":"Erbagci Z","year":"2002","unstructured":"Erbagci Z. Childhood bullous pemphigoid following hepatitis B immunization. J Dermatol. 2002, 29:781-5. 10.1111\/j.1346-8138.2002.tb00223.x","journal-title":"J Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9050435","article-title":"Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA\/DNA SARS-CoV-2 vaccination","volume":"9","author":"Watad A","year":"2021","unstructured":"Watad A, De Marco G, Mahajna H, et al.. Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA\/DNA SARS-CoV-2 vaccination. Vaccines (Basel). 2021, 9:10.3390\/vaccines9050435","journal-title":"Vaccines (Basel)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-021-04792-9","article-title":"SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis","volume":"41","author":"Velikova T","year":"2021","unstructured":"Velikova T, Georgiev T. SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis. Rheumatol Int. 2021, 41:509-18. 10.1007\/s00296-021-04792-9","journal-title":"Rheumatol Int"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/83756-bullous-pemphigoid-following-the-moderna-mrna-1273-vaccine","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:37:15Z","timestamp":1707507435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/83756-bullous-pemphigoid-following-the-moderna-mrna-1273-vaccine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,13]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.24126","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,13]]}}}